Matches in SemOpenAlex for { <https://semopenalex.org/work/W2352254236> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2352254236 abstract "Objective To observe the anticancer efficacy of ginsenoside Rg3 on colorectal cancer in vitro and in vivo. Methods Mice colorectal cell line(CT26) was incubated in 96-well plates(3×103-4×103 per well) with various concentrations of ginsenoside Rg3(0, 5, 10, 15, 20 μg/m L) for 24 hours and 48 hours. 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-dipheny 1-2-H-tetrazolium bromide assay was used to detect the inhibitory rate of cells. Xenograft models were established by subcutaneous implantation of CT26 cells into BABL/c mice. EacThmouse was injected with 1×107 cells suspended in serum-free medium. Xenograft mice were randomized into four groups: physiological saline group, ginsenoside Rg3 5 mg/kg group, ginsenoside Rg3 10 mg/kg group, and ginsenoside Rg3 20 mg/kg group. Ginsenoside Rg3 was administrated to mice by intragastric gavage. All animals were observed for activity, body weight, tumor size, survival time, mental state and adverse ef ect of ginsenoside Rg3. Hematoxylin-eosin stain was used for comparing necrosis rate among groups. Results The inhibitory rates of cells were increasing following the elevating concentrations of ginsenoside Rg3. The anti-proliferation ef ect of ginsenoside Rg3 for 48 hours was weaker than the anti-proliferation ef ect for 24 hours. The decrease of mice body weight was slower than physiological saline group after administration of ginsenoside Rg3, and the number of mice with worse physiological state, lack of activity and loss of appetite in physiological saline group were more than that in ginsenoside Rg3 groups. However, these results among four groups were not significantly dif erent(P 0.05). There were no obvious adverse ef ects of ginsenoside Rg3 found during the whole study. The necrosis rate of physiological saline group, Rg3 10 mg/kg group and Rg3 20 mg/kg group was 20%, 60% and 80% respectively. Conclusions Ginsenoside Rg3, as a single agent, still has anticancer activity. The anticancer efficacy is increasing following the elevating concentrations of ginsenoside Rg3. Ginsenoside Rg3 is a dose dependent agent." @default.
- W2352254236 created "2016-06-24" @default.
- W2352254236 creator A5044942622 @default.
- W2352254236 date "2015-01-01" @default.
- W2352254236 modified "2023-09-24" @default.
- W2352254236 title "Anticancer Effect of Ginsenoside Rg3 on Mice Colorectal Cancer" @default.
- W2352254236 hasPublicationYear "2015" @default.
- W2352254236 type Work @default.
- W2352254236 sameAs 2352254236 @default.
- W2352254236 citedByCount "0" @default.
- W2352254236 crossrefType "journal-article" @default.
- W2352254236 hasAuthorship W2352254236A5044942622 @default.
- W2352254236 hasConcept C121608353 @default.
- W2352254236 hasConcept C125473707 @default.
- W2352254236 hasConcept C126322002 @default.
- W2352254236 hasConcept C142724271 @default.
- W2352254236 hasConcept C150903083 @default.
- W2352254236 hasConcept C197934379 @default.
- W2352254236 hasConcept C204232928 @default.
- W2352254236 hasConcept C204787440 @default.
- W2352254236 hasConcept C207001950 @default.
- W2352254236 hasConcept C2776390293 @default.
- W2352254236 hasConcept C2776539398 @default.
- W2352254236 hasConcept C2777397205 @default.
- W2352254236 hasConcept C2779232237 @default.
- W2352254236 hasConcept C526805850 @default.
- W2352254236 hasConcept C71924100 @default.
- W2352254236 hasConcept C86803240 @default.
- W2352254236 hasConcept C98274493 @default.
- W2352254236 hasConceptScore W2352254236C121608353 @default.
- W2352254236 hasConceptScore W2352254236C125473707 @default.
- W2352254236 hasConceptScore W2352254236C126322002 @default.
- W2352254236 hasConceptScore W2352254236C142724271 @default.
- W2352254236 hasConceptScore W2352254236C150903083 @default.
- W2352254236 hasConceptScore W2352254236C197934379 @default.
- W2352254236 hasConceptScore W2352254236C204232928 @default.
- W2352254236 hasConceptScore W2352254236C204787440 @default.
- W2352254236 hasConceptScore W2352254236C207001950 @default.
- W2352254236 hasConceptScore W2352254236C2776390293 @default.
- W2352254236 hasConceptScore W2352254236C2776539398 @default.
- W2352254236 hasConceptScore W2352254236C2777397205 @default.
- W2352254236 hasConceptScore W2352254236C2779232237 @default.
- W2352254236 hasConceptScore W2352254236C526805850 @default.
- W2352254236 hasConceptScore W2352254236C71924100 @default.
- W2352254236 hasConceptScore W2352254236C86803240 @default.
- W2352254236 hasConceptScore W2352254236C98274493 @default.
- W2352254236 hasLocation W23522542361 @default.
- W2352254236 hasOpenAccess W2352254236 @default.
- W2352254236 hasPrimaryLocation W23522542361 @default.
- W2352254236 hasRelatedWork W1979663197 @default.
- W2352254236 hasRelatedWork W2108686552 @default.
- W2352254236 hasRelatedWork W2122708593 @default.
- W2352254236 hasRelatedWork W2160112672 @default.
- W2352254236 hasRelatedWork W2350253409 @default.
- W2352254236 hasRelatedWork W2351471000 @default.
- W2352254236 hasRelatedWork W2351952608 @default.
- W2352254236 hasRelatedWork W2359107428 @default.
- W2352254236 hasRelatedWork W2366271449 @default.
- W2352254236 hasRelatedWork W2369201877 @default.
- W2352254236 hasRelatedWork W2381523521 @default.
- W2352254236 hasRelatedWork W2388762021 @default.
- W2352254236 hasRelatedWork W2389235025 @default.
- W2352254236 hasRelatedWork W2389631441 @default.
- W2352254236 hasRelatedWork W2389789178 @default.
- W2352254236 hasRelatedWork W2393951223 @default.
- W2352254236 hasRelatedWork W3031463911 @default.
- W2352254236 hasRelatedWork W3104479345 @default.
- W2352254236 hasRelatedWork W1824085087 @default.
- W2352254236 hasRelatedWork W2171144249 @default.
- W2352254236 isParatext "false" @default.
- W2352254236 isRetracted "false" @default.
- W2352254236 magId "2352254236" @default.
- W2352254236 workType "article" @default.